Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.58 Insider Own2.30% Shs Outstand24.07M Perf Week-14.62%
Market Cap6.29B Forward P/E- EPS next Y-8.47 Insider Trans-59.11% Shs Float17.04M Perf Month-8.39%
Income-76.60M PEG- EPS next Q-1.90 Inst Own68.20% Short Float15.00% Perf Quarter19.39%
Sales2.80M P/S2247.62 EPS this Y-262.50% Inst Trans5.45% Short Ratio3.94 Perf Half Y67.68%
Book/sh17.86 P/B14.64 EPS next Y0.10% ROA-24.00% Target Price414.56 Perf Year12.98%
Cash/sh16.70 P/C15.66 EPS next 5Y18.01% ROE-26.00% 52W Range128.50 - 349.08 Perf YTD67.60%
Dividend- P/FCF- EPS past 5Y0.00% ROI-49.00% 52W High-25.10% Beta-
Dividend %- Quick Ratio22.50 Sales past 5Y- Gross Margin- 52W Low103.47% ATR16.34
Employees136 Current Ratio22.50 Sales Q/Q250.00% Oper. Margin- RSI (14)43.67 Volatility7.05% 5.85%
OptionableYes Debt/Eq0.00 EPS Q/Q85.10% Profit Margin- Rel Volume0.76 Prev Close265.69
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume649.03K Price261.46
Recom1.80 SMA20-5.35% SMA50-6.02% SMA20014.68% Volume492,252 Change-1.59%
May-21-15Initiated Barclays Overweight $425
May-19-15Downgrade BofA/Merrill Buy → Neutral
Apr-17-15Initiated UBS Buy $465
Mar-17-15Initiated MLV & Co Hold $273
Jan-28-15Reiterated Oppenheimer Outperform $499 → $375
Dec-04-14Initiated Robert W. Baird Outperform $258
Dec-03-14Reiterated FBR Capital Underperform $125 → $99
Nov-10-14Reiterated FBR Capital Underperform $172 → $125
Aug-15-14Initiated FBR Capital Underperform $172
Aug-12-14Reiterated RBC Capital Mkts Outperform $425 → $500
Jul-01-14Initiated RBC Capital Mkts Outperform $425
May-15-14Initiated Summer Street Research Buy $650
May-08-14Reiterated Oppenheimer Outperform $525 → $499
Mar-18-14Reiterated Needham Buy $320 → $500
Mar-14-14Reiterated Oppenheimer Outperform $360 → $525
Jan-10-14Reiterated Oppenheimer Outperform $94 → $360
Jan-10-14Reiterated Needham Buy $55 → $320
Oct-01-13Reiterated Oppenheimer Outperform $64 → $94
Aug-13-13Reiterated Needham Buy $40 → $55
Jul-11-13Reiterated Oppenheimer Outperform $60 → $64
May-22-15 09:02PM  Will This Drug Beat Gilead to Market in NASH? at Investopedia
May-21-15 02:19PM  Biotech: Don't Bet Against Small Caps Just Yet at Barrons.com
12:22PM  Coverage initiated on Intercept Pharma by Barclays
10:27AM  Two Picks Boosted by Intercept NASH Trial at Barrons.com
09:00AM  4 SMID-Cap Biotechs Barclays Just Confessed It Loves
May-20-15 03:25PM  Intercept Pharmaceuticals Reveals Phase III OCA Study Plan - Analyst Blog
08:45AM  Intercept Pharmaceuticals (ICPT) in Focus: Stock Tanks 16.1% - Tale of the Tape
08:27AM  Intercept Pharmaceuticals Downgraded
May-19-15 05:36PM  Stock Pops & Drops: GPRO, ICPT, RIG & RCL -16.08%
05:27PM  Intercept's NASH Trial Design Irks Investors at Investor's Business Daily
04:15PM  Intercept Drops as Liver Trial Will Be Larger Than Expected at Bloomberg
02:00PM  Is This the End of the Growth Phase for Intercept? at 24/7 Wall St.
11:02AM  Bluebird Bio, Intercept Pharma Reach Accords on Pivotal Trial Designs at TheStreet
06:00AM  Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH GlobeNewswire
May-16-15 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials
May-13-15 10:56AM  Intercept Pharmaceuticals Breaks Out
May-11-15 04:26PM  Intercept Pharma (ICPT) Stock Rose Following Earnings Release at TheStreet
08:35AM  Intercept Pharmaceuticals' (ICPT) Loss Widens in Q1 - Tale of the Tape
08:31AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
07:07AM  Q1 2015 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
06:42AM  Intercept reports 1Q loss
06:01AM  Intercept Pharmaceuticals Announces First Quarter 2015 Financial Results GlobeNewswire
May-07-15 05:23PM  Will Intercept Pharmaceuticals (ICPT) Miss on Q1 Earnings? - Analyst Blog
May-04-15 04:24PM  Intercept to Report First Quarter 2015 Financial Results on May 11 and Present at Upcoming Conferences at noodls
04:05PM  Intercept to Report First Quarter 2015 Financial Results on May 11 and Present at Upcoming Conferences GlobeNewswire
Apr-30-15 09:26PM  Gilead CEO: We are taking suggestions on companies to buy at Fortune -5.22%
Apr-24-15 05:24PM  Intercept Pharmaceuticals Releases Data on Lead Drug - Analyst Blog
09:12AM  Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug at TheStreet
Apr-23-15 03:53AM  Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients at noodls
03:35AM  Intercept Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution and Cirrhosis Prevention in High-Risk NASH Patients GlobeNewswire
Apr-18-15 11:20AM  4 Biotech and Pharma Stocks Projected to Rise 50% to 100% at 24/7 Wall St.
Apr-17-15 04:28PM  It was a day to forget on Wall Street...
02:33PM  Street Talk: ICPT under the radar
Apr-13-15 06:37AM  Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015 at noodls
06:01AM  Intercept Announces New Data in PBC and NASH to be Presented at EASL 2015 GlobeNewswire
Apr-10-15 01:10PM  Biotech Investors: Nomura Says To Watch These Dates
Apr-08-15 02:51PM  Options Pro Says Intercept Shares Will Go 'Much Higher' Through The End Of The Year
Apr-07-15 07:41PM  Regulus Soars As AstraZeneca Grabs NASH Drug Rights at Investor's Business Daily
Apr-06-15 04:22PM  Intercept Pharmaceuticals Announces Completion of Public Offering at noodls
04:10PM  Intercept Pharmaceuticals Announces Completion of Public Offering GlobeNewswire
Apr-04-15 09:15AM  Massive Biotech Stock Sale Highlights Insider Selling Report at 24/7 Wall St.
Apr-02-15 05:14PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events
Mar-31-15 05:45PM  Stock Pops & Drops: DHI, ICPT, PCLN & DANG
12:41PM  Esperion Therapeutics Inc (ESPR), Intercept Pharmaceuticals Inc (ICPT): Visium and OrbiMeds Recent Activity in Biotech at Insider Monkey
09:23AM  Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock at noodls
09:14AM  Intercept Prices 1.2M Shares, Proceeds To Be ~$338.4M
09:13AM  Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
08:51AM  Genfit's French Fans Fume Following Failure of Fatty Liver Drug at TheStreet
07:51AM  Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more at CNBC
06:48AM  Intercept Pharmaceuticals Announces Proposed Offering of Common Stock at noodls
06:24AM  Intercept Pharmaceuticals Announces Proposed Offering of Common Stock GlobeNewswire
Mar-28-15 09:10AM  Insiders Join the Selling Party as Markets Post Steep Drop at 24/7 Wall St.
Mar-27-15 03:30PM  Genfit sinks 31%, but CEO defends liver drug results at CNBC
02:20PM  Drug trial setbacks
01:06PM  Genfit's Loss Is Gain For Intercept Pharmaceuticals
09:40AM  Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study at TheStreet
Mar-26-15 06:07PM  Nasdaq stocks posting largest percentage increases AP +8.46%
02:53PM  GenFit NASH Data Drives Up Rival Intercept at Investor's Business Daily
12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
Mar-24-15 07:43AM  Why Intercept Might Be A Better Bet Than Biogen Right Now
Mar-20-15 09:28AM  What Were Trading
08:59AM  Stock Futures Up, Dollar Mixed; Nasdaq Zeros In On Fresh High at Investor's Business Daily
06:28AM  Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH at noodls
05:58AM  Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH GlobeNewswire
Mar-18-15 04:10PM  Is Intercept The Next Biotech To Break Out?
Mar-16-15 07:00PM  Lightning Round: The downgrade was wrong on this at CNBC
02:57PM  Intercept Pharmaceuticals Revisits $300 For The First Time In 7 Months
Mar-13-15 01:19PM  Biotech bull case: MNK & ICPT
Mar-11-15 09:58AM  Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know. at TheStreet +6.14%
Mar-09-15 03:32PM  Intercept Pharmaceuticals Announces 2014 Financial Results at noodls
02:34PM  Three Reasons to Fear Biotech Stocks Right Now at Barrons.com
Mar-02-15 10:48AM  Intercept Pharma (ICPT) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
07:45AM  Intercept Pharmaceuticals (ICPT) Loss Narrows in Q4 - Tale of the Tape
07:07AM  Q4 2014 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
06:41AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
06:25AM  Intercept to Report Full Year 2014 Financial Results on March 2 and Present at Upcoming Conferences at noodls
06:21AM  Intercept misses 4Q profit forecasts AP
06:00AM  Intercept Pharmaceuticals Announces 2014 Financial Results GlobeNewswire
Feb-28-15 08:01PM  Intercept Pharmaceuticals (ICPT): Will It Miss Q4 Earnings? - Analyst Blog Zacks
Feb-25-15 06:06AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online
Feb-23-15 06:00AM  Intercept to Report Full Year 2014 Financial Results on March 2 and Present at Upcoming Conferences GlobeNewswire
Feb-19-15 04:27PM  Intercept Announces Promotion of Lisa Bright to Chief Commercial & Corporate Affairs Officer GlobeNewswire
Feb-17-15 02:56PM  One ETF Gets a Lift From Rosetta Genomics ETF Trends
Feb-10-15 04:05PM  Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares GlobeNewswire
Feb-06-15 09:25AM  Intercept Pharmaceuticals (ICPT) Jumps: Stock Adds 9.5% - Tale of the Tape Zacks
06:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events EDGAR Online
Feb-04-15 07:34PM  Intercept Pharmaceuticals Announces Pricing of Public Offering GlobeNewswire
Feb-03-15 04:10PM  Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-30-15 05:13PM  Intercept absolutely a buy: Pro CNBC +17.77%
04:54PM  Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog Zacks
04:50PM  Another absolutely wild day on Wall Street Yahoo Finance Contributors
04:41PM  Intercept Jumps on Breakthrough Status for Liver Treatment at Bloomberg
02:37PM  Intercept Pharmaceuticals -- Where Are The Mega Millions? at Forbes
06:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:00AM  This ETF Should Like the Intercept Pharma News ETF Trends
Jan-29-15 04:05PM  Intercept Receives Breakthrough Therapy Designation From FDA for Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis GlobeNewswire
Jan-22-15 01:38PM  Deutsche Bank: No Big Move In FY15 For Intercept Pharmaceuticals Benzinga
Jan-12-15 09:26AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo EDGAR Online
08:00AM  Intercept Provides 2014 Year-End Update and Planned 2015 Milestones GlobeNewswire
Jan-07-15 04:05PM  Intercept to Present at the J.P. Morgan 33rd Annual Healthcare Conference GlobeNewswire
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company's product candidates in preclinical stage include INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist used in treating type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILLIAMS NICOLEDirectorMay 20Option Exercise9.829739,5571,935May 22 09:00 PM
WILLIAMS NICOLEDirectorMay 20Sale260.20973253,175962May 22 09:00 PM
AKKARAJU SRINIVASDirectorMay 19Option Exercise21.501,00021,5008,642May 22 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Option Exercise8.673,50030,33322,793May 19 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Sale306.904,2791,313,24418,514May 19 09:01 PM
Pruzanski MarkCEO & PresidentMay 14Option Exercise8.675,00043,334500,743May 18 09:00 PM
Pruzanski MarkCEO & PresidentMay 14Sale300.005,0001,500,000495,743May 18 09:00 PM
VEITINGER KLAUS R DRDirectorMay 11Option Exercise21.503918,4072,557May 13 09:00 PM
VEITINGER KLAUS R DRDirectorMay 11Sale279.07391109,1172,166May 13 09:00 PM
Adorini LucianoChief Scientific OfficerMay 06Option Exercise8.674,00034,66714,060May 08 09:00 PM
Adorini LucianoChief Scientific OfficerMay 06Sale259.974,0001,039,86310,060May 08 09:00 PM
Pruzanski MarkCEO & PresidentMay 01Option Exercise8.6712,500108,334508,243May 05 09:00 PM
Pruzanski MarkCEO & PresidentMay 01Sale253.5612,5003,169,495495,743May 05 09:00 PM
WILLIAMS NICOLEDirectorApr 20Option Exercise9.829749,5671,936Apr 22 09:00 PM
WILLIAMS NICOLEDirectorApr 20Sale278.50974271,259962Apr 22 09:00 PM
VEITINGER KLAUS R DRDirectorApr 10Option Exercise21.503918,4072,557Apr 14 09:00 PM
VEITINGER KLAUS R DRDirectorApr 10Sale272.10391106,3912,166Apr 14 09:00 PM
Duncan Barbara GayleChief Financial OfficerApr 02Sale277.703910,83017,523Apr 03 09:01 PM
Pruzanski MarkCEO & PresidentApr 02Sale277.7015743,599495,743Apr 03 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentApr 02Sale277.70843234,10219,293Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Option Exercise8.822,33420,58022,752Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Sale274.462,616718,00020,136Apr 03 09:01 PM
Duncan Barbara GayleChief Financial OfficerMar 27Sale289.821,000289,81716,264Apr 01 10:00 AM
SILVERSTEIN JONATHANDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:59 PM
ORBIMED ADVISORS LLCDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:58 PM
SILVERSTEIN JONATHANDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:28 PM
WILLIAMS NICOLEDirectorMar 20Option Exercise9.829739,5571,935Mar 24 09:00 PM
WILLIAMS NICOLEDirectorMar 20Sale305.36973297,115962Mar 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Option Exercise10.403,50036,40022,296Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Sale286.903,5001,004,14018,796Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Option Exercise8.675,00043,33423,796Mar 16 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Sale285.995,0001,429,93818,796Mar 16 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Option Exercise21.503918,4072,557Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Sale262.06391102,4652,166Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 24Option Exercise21.5063213,5882,798Feb 26 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 24Sale222.50632140,6202,166Feb 26 09:00 PM
WILLIAMS NICOLEDirectorFeb 20Option Exercise9.829749,5671,936Feb 24 09:00 PM
WILLIAMS NICOLEDirectorFeb 20Sale216.00974210,384962Feb 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 17Option Exercise9.368,79482,28223,442Feb 19 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 17Sale209.414,646972,92118,796Feb 19 09:02 PM
VEITINGER KLAUS R DRDirectorFeb 10Option Exercise21.502335,0102,399Feb 12 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 10Sale195.5223345,5562,166Feb 12 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 30Option Exercise9.487,50071,06722,148Feb 03 09:00 PM
Regan Daniel PaulChief Commercial OfficerJan 30Option Exercise37.699,847371,13311,111Feb 03 09:01 PM
Regan Daniel PaulChief Commercial OfficerJan 30Sale201.079,8471,979,9631,264Feb 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJan 30Sale205.847,5001,543,83214,648Feb 03 09:00 PM
WILLIAMS NICOLEDirectorJan 20Option Exercise9.829739,5572,438Jan 22 09:00 PM
WILLIAMS NICOLEDirectorJan 20Sale151.32973147,2341,465Jan 22 09:00 PM
VEITINGER KLAUS R DRDirectorJan 12Option Exercise21.502335,0102,399Jan 14 09:00 PM
VEITINGER KLAUS R DRDirectorJan 12Sale150.0123334,9522,166Jan 14 09:00 PM
Regan Daniel PaulChief Commercial OfficerJan 05Sale176.4914625,7671,264Jan 07 09:03 PM
Pruzanski MarkCEO & PresidentJan 05Sale176.4946181,360491,032Jan 07 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentJan 05Sale172.63664114,62714,648Jan 07 09:01 PM
Duncan Barbara GayleChief Financial OfficerJan 05Sale176.4914124,88417,264Jan 07 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 02Option Exercise31.901,00031,90018,405Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 02Sale158.7137659,67515,312Jan 05 09:01 PM
Duncan Barbara GayleChief Financial OfficerJan 02Sale156.401,000156,40017,405Jan 05 09:00 PM
Benatti LucaDirectorDec 15Buy139.86800111,8881,292Dec 15 09:00 PM
VEITINGER KLAUS R DRDirectorDec 10Option Exercise21.502335,0102,399Dec 12 09:00 PM
VEITINGER KLAUS R DRDirectorDec 10Sale144.1623333,5892,166Dec 12 09:00 PM
Pruzanski MarkCEO & PresidentNov 19Option Exercise8.736,71658,603486,625Nov 20 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 17Option Exercise10.404,00041,60018,855Nov 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 17Sale158.824,790760,73014,065Nov 19 09:00 PM
AKKARAJU SRINIVASDirectorNov 12Buy167.192,000334,3877,642Nov 13 09:32 AM
AKKARAJU SRINIVASDirectorNov 11Option Exercise21.502,50053,7505,642Nov 13 09:32 AM
VEITINGER KLAUS R DRDirectorNov 10Option Exercise21.502335,0102,399Nov 12 09:00 PM
VEITINGER KLAUS R DRDirectorNov 10Sale175.9523340,9962,166Nov 12 09:00 PM
Pruzanski MarkCEO & PresidentNov 03Option Exercise8.6710,00086,667489,909Nov 05 09:00 PM
Pruzanski MarkCEO & PresidentNov 03Sale259.4110,0002,594,124479,909Nov 05 09:00 PM
VEITINGER KLAUS R DRDirectorOct 10Option Exercise21.503918,4072,557Oct 15 09:00 PM
VEITINGER KLAUS R DRDirectorOct 10Sale223.6539187,4472,166Oct 15 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 02Sale233.97832194,66414,855Oct 03 09:00 PM
Pruzanski MarkCEO & PresidentOct 01Option Exercise8.6710,00086,667489,909Oct 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerOct 01Option Exercise31.901,00031,90017,107Oct 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentOct 01Option Exercise10.404,00041,60019,875Oct 03 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 01Sale231.174,188968,13015,687Oct 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerOct 01Sale233.121,000233,11916,107Oct 03 09:01 PM
Pruzanski MarkCEO & PresidentOct 01Sale228.8210,0002,288,187479,909Oct 03 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Option Exercise10.404,00041,60018,253Sep 17 09:04 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Sale281.194,0001,124,75114,253Sep 17 09:04 PM
VEITINGER KLAUS R DRDirectorSep 10Option Exercise21.503918,4072,557Sep 12 09:00 PM
VEITINGER KLAUS R DRDirectorSep 10Sale280.50391109,6762,166Sep 12 09:00 PM
Pruzanski MarkCEO & PresidentSep 02Option Exercise8.6710,00086,667485,042Sep 04 09:11 PM
Pruzanski MarkCEO & PresidentSep 02Sale286.4910,0002,864,883475,042Sep 04 09:11 PM
Shapiro DavidCMO and EVP - DevelopmentAug 27Option Exercise8.6710,00086,66724,253Aug 29 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 27Sale293.9310,0002,939,28614,253Aug 29 09:00 PM
SILVERSTEIN JONATHANDirectorAug 26Sale300.0761,25818,381,5881,485,324Aug 27 09:06 PM
ORBIMED ADVISORS LLCDirectorAug 26Sale300.0761,25818,381,5881,485,324Aug 27 09:05 PM
SILVERSTEIN JONATHANDirectorAug 25Sale295.5950,00014,779,4991,546,582Aug 27 09:06 PM
ORBIMED ADVISORS LLCDirectorAug 25Sale295.5950,00014,779,4991,546,582Aug 27 09:05 PM
WILLIAMS NICOLEDirectorAug 25Sale295.082,433717,9191,465Aug 27 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 15Option Exercise10.404,00041,60019,027Aug 15 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 15Sale291.494,7741,391,56814,253Aug 15 09:00 PM
SILVERSTEIN JONATHANDirectorAug 14Sale299.8260,00017,989,2071,596,582Aug 18 09:13 PM
ORBIMED ADVISORS LLCDirectorAug 14Sale299.8260,00017,989,2071,596,582Aug 18 09:07 PM